ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer

This study uses a blood test called ctDNA (circulating tumor DNA) to guide treatment decisions for people with advanced colorectal cancer that doesn't respond well to immunotherapy on its own. It tests a combination of a targeted drug (a TKI) plus an immunotherapy (anti-PD-1) for this specific cancer type. **You may be eligible if...** - You are 18–80 years old with confirmed advanced or recurrent colorectal cancer - Your tumor is classified as pMMR or MSS (meaning standard immunotherapy alone is unlikely to work) - Your ctDNA level in the blood is below a certain threshold - Your cancer has progressed after standard chemotherapy regimens - You are in good physical condition (ECOG 0–1) **You may NOT be eligible if...** - Your cancer is classified as dMMR or MSI-H - You have had recent systemic therapy within 28 days - You have uncontrolled infections or serious organ problems - You have active autoimmune disease Talk to your doctor to see if this trial is right for you.